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Summary
Objectives: We evaluated the prevalence of multidrug resistance (MDR) and production of
extended spectrum beta-lactamase (ESBL) by Salmonella enterica (serotypes Typhi and Paratyphi
A) in a teaching hospital in Nepal. The MDR strains of S. entericawere also tested for susceptibility
to newer antibiotics.
Methods: Blood cultures were obtained from 4105 patients with febrile illnesses. Isolates of S.
enterica were serotyped and antibiotic susceptibility testing was carried out using disk diffusion
(Kirby—Bauer) and E-tests. ESBL screening and phenotype confirmation were done following
National Committee for Clinical Laboratory Standards (NCCLS) recommendations for Escherichia
coli.
Results: A total of 541 isolates of S. enterica serotypes Typhi (47%) and Paratyphi A (53%) were
grown. Twenty-eight isolates (5%) of S. enterica were resistant to two or more antibiotics (MDR
isolates), with a greater prevalence among serotype Paratyphi A (7%). All ESBL producers (three
isolates) were serotype Paratyphi A. Most of the MDR S. enterica showed reduced susceptibility to
ampicillin, chloramphenicol, trimethoprim—sulfamethoxazole, ofloxacin, and ciprofloxacin, and
had good susceptibility to extended-spectrum cephalosporins and carbapenems. Among the
fluoroquinolones, gatifloxacin demonstrated better in vitro activity compared to levofloxacin,
ciprofloxacin, and ofloxacin.§ Presented at the Ninth Conference of the International Society of Travel Medicine (CISTM), Lisbon, Portugal, May 1—5, 2005.
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Multidrug-resistant ESBL-producing Salmonella enterica 435Conclusions: A greater prevalence of S. enterica serotype Paratyphi Awith higher rates of multidrug
resistance and ESBL production is concerning for natives as well as travelers in Nepal since the
current typhoid vaccines do not provide protection against this serotype.
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Enteric fever continues to be amajor health problem in under-
developed countries including South Asian nations. It afflicts
local inhabitants as well as travelers to endemic areas.
Increasing multidrug resistance in Salmonella enterica sero-
type Typhi has been reported from various parts of the
world.1—4 Similarly, the causative agent of a less severe
variety of enteric fever, S. enterica serotype Paratyphi A,
has also been reported to have developed resistance to multi-
ple antibiotics.5 Epidemiological studies using the pulsed
field gel electrophoresis (PFGE) technique have established
that multidrug-resistant S. enterica serotype Typhi isolates
circulating in Asia are not derived from a single clone.6
Enteric fever is endemic in Nepal. S. enterica serotype
Typhi and S. enterica serotype Paratyphi A have been
reported as the most common culture isolates from patients
with febrile illnesses needing hospital admission.7,8 Over the
past decade, increasing antibiotic resistance in S. enterica
has lead to a shift in the antibiotics used against this organism
from chloramphenicol and ampicillin to trimethoprim—sulfa-
methoxazole, fluoroquinolones (ofloxacin, ciprofloxacin),
and ceftriaxone. Even with the use of these antibiotics,
the positive response to treatment has only been in the range
of 16—40% in Nepal.8 The oral Ty21a and parenteral Vi
polysaccharide typhoid vaccines provide protection against
the serotype Typhi only. Currently there is no vaccine avail-
able for the Paratyphi serotypes.
The primary objective of this study was to determine the
prevalence of multidrug resistance (MDR) and extended-
spectrum beta-lactamase (ESBL)-producing phenotypes
among the bloodstream isolates of S. enterica serotypes
Typhi and Paratyphi A. We also evaluated the antibiotic
susceptibility pattern of these MDR and ESBL-producing
isolates to three relatively new antibiotics — gatifloxacin,
levofloxacin, and ertapenem — in a search for an appro-
priate alternative. This is the first study done in Nepal
exploring the presence of MDR and ESBL-producing strains
of S. enterica.
Materials and methods
This study was conducted from January to September 2004,
at Tribhuvan University Teaching Hospital, a referral center
with 450 beds in Kathmandu, Nepal. Blood samples were
obtained from febrile patients with clinically suspected
enteric fever. Identification of bacteria was done using stan-
dard microbiological techniques.9—11 Serotyping of S. enter-
ica was done using polyvalent O-antisera A—G and individual
O and H-antisera (Denka Seiken, Japan).
Susceptibility tests for S. enterica serotype Typhi and Para-
typhi A were performed using standard disk diffusion (Kirby—
Bauer) methods and following National Committee for Clinical
Laboratory Standards (NCCLS) recommendations.9—12 Theantibiotics tested included: ampicillin, chloramphenicol,
ciprofloxacin, ofloxacin, trimethoprim—sulfamethoxazole,
cefotaxime, ceftriaxone, ceftazidime, and imipenem. We
labeled isolates as MDR if they were resistant to at least two
classes of first-line agents including ampicillin, chloramphe-
nicol, trimethoprim—sulfamethoxazole, fluoroquinolones
(ciprofloxacin andofloxacin), andcephalosporins (cefotaxime,
ceftriaxone, and ceftazidime). Escherichia coli ATCC 25922
was used for quality control.
All the isolates of S. enterica were screened for ESBL
production using both ceftazidime and cefotaxime discs
(Becton, Dickinson & Company, USA) following the NCCLS
criteria for E. coli and Klebsiella pneumoniae.12 The organ-
isms showing zones of inhibition (ZOI) 22 mm and 27 mm
for ceftazidime and cefotaxime, respectively, were also
tested in combination with clavulanic acid. The organisms
were phenotypically confirmed as ESBL producers when they
showed an increase in ZOI by greater than or equal to 5 mm
when evaluated in combination with clavulanic acid. Quality
control was performed by testing Escherichia coli ATCC
25922.
The MDR isolates of S. enterica were also tested against
newer antibiotics including gatifloxacin, levofloxacin, and
ertapenem. The minimum inhibitory concentrations (MICs)
of these antibiotics were determined by using the E-test (AB
Biodisk, Sweden) following standard procedures as recom-
mended by the manufacturer. Antibiotic breakpoints per
NCCLS guidelines were used to determine the susceptibil-
ities.12
Statistical comparisons of prevalence rates between the
two serotypes and differences in resistance rates against
antibiotics were done by Fisher’s exact tests and Chi-square
tests using SPSS software version 12.0 (SPSS Inc., Chicago,
USA).
Results
Between January and September 2004, we collected 4105
blood culture samples from patients with a febrile illness
visiting Tribhuvan University Teaching Hospital, Kathmandu.
Blood cultures obtained from 667 (16%) patients were posi-
tive for bacterial growth with 541 non-duplicate isolates (81%
of positive cultures) of S. enterica. Serotyping showed that
253 (47%) of these isolates were S. enterica serotype Typhi
and 288 isolates (53%) were S. enterica serotype Paratyphi A
( p = 0.03). Among these 541 isolates of S. enterica, 28 (5%)
were resistant to two or more antibiotics and were classified
as MDR isolates. A greater proportion of S. enterica serotype
Paratyphi Awas MDR (21 isolates, 7%) compared to S. enterica
serotype Typhi (seven isolates, 3%) ( p = 0.02).
The MDR isolates of S. enterica serotype Typhi demon-
strated poor susceptibility to oral antibiotics including
ampicillin (43%), chloramphenicol (29%), trimethoprim—sul-
famethoxazole (29%), ofloxacin (57%), and ciprofloxacin
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Table 1 Antibiotic susceptibilities of multidrug-resistant Salmonella enterica serotypes Typhi and Paratyphi A by Kirby—Bauer
method
Antibiotics Serotype Typhi (N = 7) Serotype Paratyphi A (N = 21)
S (%) MS (%) R (%) S (%) MS (%) R (%)
Ampicillin 3 (43) 0 (0) 4 (57) 16 (76) 1 (5) 4 (19)
Chloramphenicol 2 (29) 1 (14) 4 (57) 10 (48) 10 (48) 1 (5)
TMP—SMX 2 (29) 0 (0) 5 (71) 19 (90) 0 (0) 2 (10)
Ciprofloxacin 4 (57) 2 (29) 1 (14) 0 (0) 14 (67) 7 (33)
Ofloxacin 4 (57) 1 (14) 2 (29) 0 (0) 3 (14) 18 (86)
Cefotaxime 7 (100) 0 (0) 0 (0) 16 (76) 3 (14) 0 (0)
Ceftriaxone 7 (100) 0 (0) 0 (0) 16 (76) 3 (14) 0 (0)
Ceftazidime 7 (100) 0 (0) 0 (0) 18 (86) 2 (10) 1 (5)
Imipenem 7 (100) 0 (0) 0 (0) 21 (100) 0 (0) 0 (0)
S, susceptible; MS, moderately susceptible; R, resistant; TMP—SMX, trimethoprim—sulfamethoxazole.(57%). All these isolates were uniformly susceptible to cepha-
losporins and carbapenems (Table 1).
All isolates of MDR S. enterica serotype Paratyphi A
demonstrated reduced susceptibility to ofloxacin and cipro-
floxacin, whereas they were all susceptible to the carbape-
nems (Table 1). Susceptibility to other antibiotics was as
follows: ampicillin (76%), chloramphenicol (48%), trimetho-
prim—sulfamethoxazole (90%), cefotaxime/ceftriaxone
(76%), and ceftazidime (86%).
When both serotypes of S. entericawere further tested for
ESBL production, only three of 541 (0.5%) isolates were found
to be ESBL producers. All three isolates belonged to the
serotype Paratyphi A.
The antimicrobial susceptibility of the MDR S. enterica
using E-tests for three relatively new antibiotics demon-
strated that 24 (86%) isolates had a MIC of <2.0 mg/mL for
gatifloxacin, whereas only nine (32%) isolates had MIC
<2.0 mg/mL for levofloxacin (Table 2). Four isolates (14%)
demonstrated reduced susceptibility to gatifloxacin: one
isolate with MIC 2—8 mg/mL (intermediate) and three iso-
lates with MIC >8 mg/mL (resistant), whereas 19 (68%) iso-
lates showed intermediate to full resistance to levofloxacin.
All isolates showed MIC of <2.0 mg/mL to ertapenem.
Comparison of the susceptibility data for the four fluoro-
quinolones demonstrated that eight (29%) isolates of MDR S.
enterica were resistant to ciprofloxacin and 19 (68%) to oflox-
acin (p < 0.01). All ciprofloxacin susceptible isolates were
further tested with nalidixic acid disks and were confirmedTable 2 Susceptibility of newer antimicrobial agents against mul
Serotypes Antibiotics (E-test)
Gatifloxacin Levoflox
S (<2
mg/mL)
MS (2—8
mg/mL)
R (>8
mg/mL)
S (<2
mg/mL)
S. enterica
Typhi (N = 7)
5 1 1 5
S. enterica
Paratyphi
(N = 21)
19 0 2 4
S, susceptible; MS, moderately susceptible; R, resistant.to be susceptible. Among the newer fluoroquinolones, only
four (14%) showed reduced susceptibility to gatifloxacin,
whereas 19 (68%) isolates had reduced susceptibility to levo-
floxacin (p < 0.01). These data suggest that among the older
fluoroquinolones, ciprofloxacin has better in vitroactivity than
ofloxacin. Gatifloxacin demonstrated a superior in vitro activ-
ity among the four fluoroquinolones studied.
Discussion
Increasing antibiotic resistance in S. enterica is a major
therapeutic concern for physicians in developing countries
where typhoid and paratyphoid fevers are endemic. In this
study, we found a greater prevalence of serotype Paratyphi A
than Typhi. A similar trend has been reported in a recent
study done in Nepal.13 In addition, we also found higher rates
of multidrug resistance and ESBL production among Paratyphi
A (7%) compared to Typhi (3%). This is of concern for travelers
visiting the region in the absence of an effective vaccine
against Paratyphi serotypes. A large outbreak of MDR S.
enterica serotype Typhi from a contaminated drinking water
supply in a small Nepali town has recently been described.14
Prevalence of MDR Salmonella varies from 0 to 61% in dif-
ferent parts of the world.15—17
Chloramphenicol, ampicillin, and trimethoprim—sulfa-
methoxazole have been widely used as the primary drugs
for the treatment of enteric fever. In our study, 71% and
53% of MDR S. enterica serotypes Typhi and Paratyphi A,tidrug-resistant Salmonella enterica isolates by E-test (N = 28)
acin Ertapenem
MS (2—8
mg/mL)
R (>8
mg/mL)
S (<2
mg/mL)
MS (2—8
mg/mL)
R (>8
mg/mL)
1 1 7 0 0
16 1 21 0 0
Multidrug-resistant ESBL-producing Salmonella enterica 437respectively, showed reduced susceptibility to chlorampheni-
col. These results are similar to other studies reporting chlor-
amphenicol resistance in S. enterica.18—20 Resistance to
chloramphenicol in S. enterica serotype Typhi was initially
reported from the UK in the 1970s. Subsequent reports came
from Greece and Israel followed by the epidemics of MDR
Salmonella inMexico, India, and other countries.1,3 Resistance
to ampicillin and trimethoprim—sulfamethoxazole in our study
is comparable to reports fromother studies in the region.3,17,18
In the 1990s, emergence of resistance to chloramphenicol
and ampicillin lead to the wider use of fluoroquinolones, such
as ciprofloxacin and ofloxacin, which were considered as
highly effective antibiotics against S. enterica.21 In our study,
only 57% of MDR S. enterica serotype Typhi were susceptible
to ofloxacin and ciprofloxacin, whereas none of the MDR
serotype Paratyphi A isolates were fully susceptible to either
of these antibiotics. The rest of the MDR isolates showed
reduced susceptibility or resistance to these fluoroquino-
lones by current MIC breakpoints. Although the efficacy of
ciprofloxacin and ofloxacin against S. enterica has previously
been shown to be relatively higher in other parts of
world,13,22,23 this study suggests that the efficacy of cipro-
floxacin and ofloxacin is poor against the MDR isolates. This
reflects the local practice of widespread use, and probably
misuse and overuse, of ciprofloxacin and ofloxacin. In addi-
tion, over-the-counter availability of these antibiotics, self-
prescription by patients, and incomplete courses of treat-
ment are probable additional factors contributing to the
development of resistance.
The third generation cephalosporins (ceftriaxone, cefo-
taxime, and ceftazidime) as well as carbapenems (imipenem
and ertapenem) showed good activity against MDR S. enter-
ica. All isolates of S. enterica serotype Typhi were susceptible
to the third generation cephalosporins, and most of the
serotype Paratyphi A were susceptible to these extended-
spectrum cephalosporins. A similar study by Gautam et al. in
India showed varied susceptibility patterns of S. enterica
serotype Typhi and Paratyphi A over a three-year period,
indicating a changing pattern of antibiotic susceptibility.3 All
isolates in our study were susceptible to both carbapenems,
confirming findings from other studies.22
This is the first study reporting ESBL production by S.
enterica in Nepal. We found only three isolates of ESBL S.
enterica (0.5%), all of which belonged to the serotype
Paratyphi A. The prevalence of ESBLs among clinical isolates
of Gram-negative organisms varies from country to country
and from institution to institution. Its prevalence in Salmo-
nella has been reported to be low so far. Szych et al. reported
0.3% occurrence of ESBL S. enterica serotype enterica in
Poland.24 A variety of Ambler class A and class C beta-
lactamases have been described in different serotypes of
Salmonella spp.25
In the search for useful alternative antibiotics against
MDR and ESBL isolates of S. enterica, we also tested gati-
floxacin, levofloxacin, and ertapenem using the E-test.
Ertapenem, a new once-daily carbapenem, was active
against 100% of MDR isolates demonstrating activity compar-
able to imipenem andmaking it a suitable substitute. Among
the fluoroquinolones, gatifloxacin was superior to levoflox-
acin, ciprofloxacin, and ofloxacin. These results concur with
the data from the SENTRYAntimicrobial Surveillance System
inwhich Salmonella spp bloodstream isolateswere collectedfrom Latin American medical centers. All of their isolates
were uniformly susceptible to gatifloxacin and merope-
nem.22 High level resistance to fluoroquinolones in S. enter-
ica is thought to be associated with two point mutations in
the gyrA gene while mutations parC and parE are considered
to be less important.25—28 It has been suggested that a low
level resistance to ciprofloxacin, probably arising from a one
point mutation in the gyrA gene, may not be detected by in
vitro susceptibility tests using the current MIC breakpoints
for ciprofloxacin. In vitro resistance to nalidixic acid can be
used to detect this low level of resistance.27,28 Further
studies will be needed to explore the mechanism of resis-
tance in the isolates collected in this study. A new method
using PCR-restriction fragment length polymorphism has
been designed to screen the gyrA mutations of S. enterica
serovars Typhi and Paratyphi Awith reduced susceptibility to
fluoroquinolones.29
Changing susceptibility patterns in S. enterica over time
have been reported.30—32 Wasfy et al. reported an increasing
prevalence of MDR Salmonella in Egypt until it reached 100%
in 1993; it later declined to 5% in 2000. This illustrates how a
change in antibiotic prescribing practices influences bacter-
ial resistance and underscores the importance of continued
surveillance of antibiotic resistance.30
In conclusion, this study demonstrated a 5% prevalence of
multidrug resistance among S. enterica at a tertiary care
hospital in Kathmandu, Nepal, with a higher rate of resis-
tance among the serotype Paratyphi A. It also showed a low
but definite presence of ESBL-producing strains (0.5%) of
Paratyphi A. These findings are concerning for the natives
of Nepal as well as travelers to the country, especially since
the current typhoid vaccines do not provide protection
against this serotype. Routine screening for ESBL production
and surveillance for emergence of resistance are recom-
mended. Clinical studies to evaluate efficacy of newer anti-
biotics against S. enterica are also desirable.
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